CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Aeglea Bio Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Aeglea Bio Therapeutics Inc
805 Las Cimas Parkway, Suite 100
Phone: (512) 942-2935p:512 942-2935 AUSTIN, TX  78746  United States Ticker: AGLEAGLE

Business Summary
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a human enzyme therapeutics as advanced solutions for rare and other high-burden diseases. The Company’s product candidates are Pegzilarginase, ACN00177 and AEB5100. Its Pegzilarginase is a recombinant human Arginase one that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase One Deficiency. Its engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. The Company is evaluating Pegzilarginase in a global pivotal Phase III PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and in a Phase II open-label extension study for patients with Arginase One Deficiency. Its ACN00177 is a PEGylated or polyethylene glycol modified, human enzyme engineered to degrade free homocysteine and homocystine in patients with Homocystinuria.
(Source: 10-Q)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/202012/31/2019YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the board Russell J.Cox 56 1/1/2019 6/1/2015
President and Chief Executive Officer, Director Anthony G.Quinn 57 10/10/2019 3/1/2016
Chief Financial Officer, Vice President Charles N.York 42 9/1/2015 7/1/2014
8 additional Officers and Directors records available in full report.

Business Names
Business Name
AE4ase, Inc.
AE5ase, Inc.
AE6ase, Inc.
6 additional Business Names available in full report.

General Information
Number of Employees: 79 (As of 3/31/2020)
Outstanding Shares: 44,593,764 (As of 5/1/2020)
Shareholders: 24
Stock Exchange: NASD
Federal Tax Id: 464312787
Fax Number: (512) 872-5121


Copyright © 2020 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, August 5, 2020